PACAP Dosing & Reconstitution Guide

Due to PACAP's classification as an endogenous neuropeptide, traditional dosing parameters such as frequency and specific dose ranges are not applicable. However, research has indicated that intravenous administration of PACAP-38 at a provocation dose of 10 pmol/kg over a 20-minute period can elicit migraine symptoms in individuals predisposed to this condition. This observation highlights the neuropeptide's potent biological activity and its relevance in migraine pathophysiology. It is essential for researchers to consider the individual variability in response to PACAP when designing experiments and to ensure that any provocation studies are conducted with caution, adhering to ethical guidelines and institutional review board approvals.

As an endogenous neuropeptide, PACAP is not utilized as a therapeutic agent, and thus, specific safety profiles in clinical settings are not established. However, studies involving intravenous PACAP-38 infusion in healthy volunteers and migraine patients have reported side effects such as headache, flushing, and palpitations. These reactions are likely attributable to PACAP's strong vasodilatory effects and its role in mast cell activation, which may lead to hypotension and allergic-type responses. Given these potential adverse effects, caution is warranted, particularly in individuals with a history of migraine, as they may exhibit heightened sensitivity to exogenous PACAP administration. This reference entry is intended solely for research purposes and should not be interpreted as a guideline for therapeutic use.